BeyondSpring Inc.

98 articles with BeyondSpring Inc.

• BeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference

  11/23/2020

  BeyondSpring Inc., a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, announced that management will provide a corporate overview at the 2020 Evercore ISI HealthCONx Conference on December 2, 2020.

• BeyondSpring Announces Pricing of Ordinary Shares - Nov 19, 2020

  11/19/2020

  BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative cancer therapies, announced the pricing of its public offering of 7,500,000 ordinary shares at a public offering price of $10.00 per share.

• BeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates

  11/17/2020

  BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced its financial results and provided an operational update for the three months ended September 30, 2020. “ We were thrilled to announce positive top-line data in our pivotal Ph

• BeyondSpring Announces Proposed Public Offering of Ordinary Shares - Nov 17, 2020

  11/17/2020

  BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative cancer therapies, announced the launch of an underwritten public offering of $75 million of its ordinary shares.

• BeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia

  11/16/2020

  Study met primary endpoint showing statistically significant improvement in rate of prevention of Grade 4 neutropenia in Cycle 1, p=0.0015

• BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly

  11/13/2020

  Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology to Develop Potential New Medicines

• 

  BioSpace Movers & Shakers, Oct. 16

  10/16/2020

  Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.

• Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer

  10/14/2020

  “Molecular Glue” Protein Degradation Serves as Alternative Approach for Difficult-to-Treat Diseases

• 

  BioSpace Movers & Shakers, Sept. 25

  9/25/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers.

• New Data Highlights BeyondSpring’s Plinabulin as a Highly Effective Agent for Preventing Chemotherapy-Induced Neutropenia, Presentation at ESMO Congress 2020

  9/24/2020

  BeyondSpring Inc . (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology therapies to transform the lives of patients with unmet medical needs, today announced new clinical data on the Company’s first-in-class late-stage asset, Plinabulin, showing that the drug candidate is a favorable option for preventing chemotherapy-induced neutropenia (CIN) during the COVID-19 pa

• BeyondSpring Appoints Elizabeth Czerepak as Chief Financial OfficerNew Subsidiary Focused on Targeted Protein Degradation, Seed Therapeutics, Appoints Edward Liu as CFO

  9/22/2020

  Following its recent receipt of two Breakthrough Therapy Designations in both the U.S. and China for Plinabulin in the chemotherapy-induced neutropenia (CIN) indication, BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced the appointment of Elizabeth Czer

• BeyondSpring to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

  9/11/2020

  - BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced that management will provide a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on Monday, September 14, 2020, at 1:00 p.m. Eastern Time. The presentation will be

• BeyondSpring Receives Breakthrough Therapy Designations from Both U.S. FDA and China NMPA for Plinabulin in Chemotherapy-Induced Neutropenia Indication

  9/8/2020

  Designation Based on PROTECTIVE-2 Phase 3 Interim Data, Reinforcing Significant Treatment Need in CIN

• BeyondSpring Provides Second-Quarter 2020 Financial Results and Business Updates

  9/3/2020

  Reported Positive Topline Pre-Specified Interim Results from PROTECTIVE-2 (Study 106) Phase 3, Demonstrating Plinabulin’s Superiority in Combination with Neulasta for CIN Prevention vs. Neulasta Alone

• BeyondSpring to Host Second-Quarter 2020 Financial Results and Operational Update Conference Call on September 3rd, 2020

  8/27/2020

  BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report its second-quarter 2020 financial results and host an operational update conference call on Thursday, September 3 rd , 2020, at 8 a.m. Eastern Time. The conference call may be accessed by dialing 1-877-451-6152 (U.S.) or 1-201-389-0879 (internati

• BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the U.S.

  8/11/2020

  - NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients - - First Patient Dosed in the U.S. Avoided Grade 4 Neutropenia in Cycle 2 with Plinabulin and Pegfilgrastim, Despite Experiencing Grade 4 Neutropenia in Cycle 1 with Pegfilgrastim Alone - NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative

• New Stem Cell-Based Application for BeyondSpring’s Plinabulin Presented at ISSCR Annual Meeting

  6/30/2020

  BeyondSpring Inc. announced that the Company presented clinical data on BeyondSpring’s first-in-class, late-stage asset, Plinabulin, showing potent CD34+ progenitor cell mobilization from bone marrow, which has broad applications for stem cell-based therapies, gene therapy and regenerative medicine.

• New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSpring’s Plinabulin

  6/23/2020

  Research Presented at 2020 AACR Virtual Annual Meeting The Triple I/O Combination of Plinabulin, Anti-PD-1 and Radiation Achieved a 100 Percent Complete Response in Anti-PD-1 Non-responsive Animal Model Triple I/O Combination to Be Administered to Patients Who Failed I/O in Second Half of 2020 NEW YORK, June 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-

• BeyondSpring Announces Pricing of Ordinary Shares - June 19, 2020

  6/19/2020

  BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, announced the pricing of its public offering of 1,930,000 ordinary shares at a public offering price of $13.00 per share.

• BeyondSpring Announces Proposed Public Offering of Ordinary Shares - June 18, 2020

  6/18/2020

  BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, announced the launch of an underwritten public offering of its ordinary shares.